Open Access
Subscription Access
Open Access
Subscription Access
Vitamin K2-7, a Promising Solution to Peripheral Neuropathy aroused due to Multiple Myeloma Treatment
Subscribe/Renew Journal
Objective: A large number of patients with Multiple Myeloma (MM) develop Peripheral Neuropathy (PN). This is either consequent upon iatrogeny with prolonged therapy or as a part of the disease. The persistence of disabling PN, during therapy, often compels the physician to a reduction in the dose of the primary agents or their total discontinuation or replacement. Our previous study with Vitamin K2-7 has shown therapeutic activity in patients with diabetic neuropathy and/or with vitamin B12 deficiency. An anecdotal observation of considerable relief of PN in an MM patient, after chemotherapy, prompted us for this observational study. The present brief communication reports the ameliorative potential of Vitamin K2-7 in the management of iatrogenic PN in MM.
Material and Methods: This communication describes a case-series of seventeen patients with iatrogenic PN for MM. Vitamin K2-7 was given orally to patients who complained of PN till 4 chemotherapy cycles and followed up to 5th chemotherapy cycle. Symptoms included tingling, numbness along with burning sensation, fatigue and cramps. This study was approved by an independent ethics committee.
Results: Twelve out of seventeen patients reported relief. Vitamin K2-7 had allowed these twelve patients continuation of treatment for MM, without any reduction of dosage or temporary discontinuation of treatment. Three patients had discontinued the MM treatment and two had discontinued Vitamin K2-7 on their own after they did not find any marked relief.
Conclusions: This preliminary observational study, to our knowledge, suggests for the first time that Vitamin K2-7 has an ameliorative potential for relief of iatrogenic PN in MM patients. The positive directionality of the outcome necessitates a larger study with an objective assessment of PN with Nerve Conduction Velocity and with the use of validated Visual Analog Scale for subjective features of PN.
Keywords
- Dimopoulos MA and Terpos E. Multiple myeloma. Ann Oncol 2010;21: vii143-50.
- Rajkumar SV and Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clinic 2016;91:101-19.
- Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology 2013;27:4-10.
- E. Terpos et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015; 100(10): 1254:66.
- Morawska M, Grzasko N, Kostyra M et al. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 2015;33:113–9.
- Fallon MT, Storey DJ, Krishan A et al. Cancer treatment-related neuropathic pain: proof of concept study with menthola TRPM8 agonist. Support Care Cancer 2015;23:2769–77.
- Kulkarni VK, Upase DP, Dound YA et al. The effect of vitamin K2-7 in peripheral neuropathy due to Vitamin B12 deficiency and/or diabetes mellitus: A Preliminary Study. The Indian Practioner 2013;66:625-9.
- Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone (pom/dex) is highly effective therapy in relapsed multiple myeloma. J Clin Oncol 2009;27:5008–14.
- Schey S and Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs 2011;20:691–700.
- Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296–306.
- Idia S, Wakabayashi M, Tsukasaki K, et al. Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma. Cancer sci 2018;109:1552-61.
- McCullough KB, Hobbs MA, Abeykoon JP et al. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Curr Hematol Maliq Rep 2018;13:114-24.
- Terpos E, Suzan F and Goldschmidt H. Going the distance: Are we losing patients along the multiple myeloma treatment pathway? Critical Reviews in Oncology/Hematology. Volume 126, June 2018, Pages 19-23.
- Windebank AJ and Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27–46.
- Vaidya ADB, Mehta DS, de Souza A, Vaidya RA. Treatment of Human Disease Conditions and Disorders using Vitamin K analogues and Derivatives. PCT/IN2008/000465, Jul 2008.
- Mehta DS, Vaidya RA, Dound YA et al. Therapeutic Activity and Safety of Vitamin K 2-7 in Muscle Cramps: An Interventional Case- Series. The Indian Practitioner 2010 May: 287-291.
- Ravishankar B, Dound YA, Mehta DS et al. Safety assessment of menaquinone-7 for use in human nutrition. J Food Drug Anal 2015;23:99-108.
- Mehta DS, Dound YA, Jadhav SS et al. A novel potential role of Vitamin K2‑7 in relieving peripheral neuropathy. J Pharmacol Pharmacother 2018;9.DOI: 10.4103/jpp.JPP_72_18.
Abstract Views: 424
PDF Views: 0